290 related articles for article (PubMed ID: 27413118)
21. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
[TBL] [Abstract][Full Text] [Related]
22. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
23. Effect of VX-770 (ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells.
Vachel L; Norez C; Becq F; Vandebrouck C
J Cyst Fibros; 2013 Dec; 12(6):584-91. PubMed ID: 23757361
[TBL] [Abstract][Full Text] [Related]
24. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
Liu X; Dawson DC
Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
[TBL] [Abstract][Full Text] [Related]
25. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
26. A single amino acid substitution in CFTR converts ATP to an inhibitory ligand.
Lin WY; Jih KY; Hwang TC
J Gen Physiol; 2014 Oct; 144(4):311-20. PubMed ID: 25225552
[TBL] [Abstract][Full Text] [Related]
27. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
28. Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.
Prins S; Langron E; Hastings C; Hill EJ; Stefan AC; Griffin LD; Vergani P
J Biol Chem; 2020 Dec; 295(49):16529-16544. PubMed ID: 32934006
[TBL] [Abstract][Full Text] [Related]
29. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs.
Miki H; Zhou Z; Li M; Hwang TC; Bompadre SG
J Biol Chem; 2010 Jun; 285(26):19967-75. PubMed ID: 20406820
[TBL] [Abstract][Full Text] [Related]
30. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
[TBL] [Abstract][Full Text] [Related]
31. Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations.
Csanády L; Töröcsik B
Elife; 2019 Jun; 8():. PubMed ID: 31205003
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of G551D-CFTR (cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog.
Bompadre SG; Li M; Hwang TC
J Biol Chem; 2008 Feb; 283(9):5364-9. PubMed ID: 18167357
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
34. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
[TBL] [Abstract][Full Text] [Related]
35. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
Van Goor F; Yu H; Burton B; Hoffman BJ
J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399
[TBL] [Abstract][Full Text] [Related]
36. Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.
Hadida S; Van Goor F; Zhou J; Arumugam V; McCartney J; Hazlewood A; Decker C; Negulescu P; Grootenhuis PD
J Med Chem; 2014 Dec; 57(23):9776-95. PubMed ID: 25441013
[TBL] [Abstract][Full Text] [Related]
37. VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level.
Cui G; Stauffer BB; Imhoff BR; Rab A; Hong JS; Sorscher EJ; McCarty NA
Sci Rep; 2019 Sep; 9(1):13460. PubMed ID: 31530897
[TBL] [Abstract][Full Text] [Related]
38. Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs.
Wang W; Li G; Clancy JP; Kirk KL
J Biol Chem; 2005 Jun; 280(25):23622-30. PubMed ID: 15857825
[TBL] [Abstract][Full Text] [Related]
39. Catalyst-like modulation of transition states for CFTR channel opening and closing: new stimulation strategy exploits nonequilibrium gating.
Csanády L; Töröcsik B
J Gen Physiol; 2014 Feb; 143(2):269-87. PubMed ID: 24420771
[TBL] [Abstract][Full Text] [Related]
40. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
